Articlenpj biomedical innovations2026
Terahertz-based prognostic framework for glioma: from spectral features to patient-level prognostic assessment.
Article in npj biomedical innovations, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
In glioma, accurate prediction of recurrence and survival is essential for clinical decision-making and individualized management. However, current prognostic tools do not fully capture outcome heterogeneity, and convenient approaches for early postoperative prognostic evaluation are lacking. We investigated whether terahertz (THz) spectroscopy could provide label-free prognostic information. In this single-center retrospective study, 56 patients were assigned to training (n = 33) and held-out internal testing (n = 23) cohorts. A total of 443 frozen sections were measured using THz time-domain spectroscopy, and patient-level features were derived from six spectral parameters across 0.2-1.4 THz. Separate progression-free survival (PFS) and overall survival (OS) signatures were developed using univariable Cox screening, LASSO-Cox selection, and multivariable Cox modeling and validated in the testing cohort. The THz-based risk score (THz-RS) significantly stratified PFS and OS in both cohorts, showed good time-dependent discrimination, and retained prognostic value after multivariable adjustment for clinicomolecular variables. Model interpretation identified the 1.2-1.3 THz band (B11) as a major contributor, while targeted LC-MS/MS revealed associations between tissue glutamate abundance and B11-derived THz features, providing preliminary biochemical support for this spectral region. These findings support THz spectroscopy as a label-free complementary tool for perioperative prognostic assessment in glioma, pending validation in larger multicenter cohorts.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.